Sun, Dec 28, 2014, 8:37 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

AMAG Pharmaceuticals, Inc. Message Board

  • bronkonagurski1908 bronkonagurski1908 Jun 22, 2009 11:09 AM Flag

    My MEDX back in the green!!!

    Is anyone long Medarex? I have owned the stock a few times over the last...10 years??? Has it been that long?? It was my biggest winner in 2000, I bought back into the stock in 2001 and then doubled down in December of 2008. I am back to breakeven. MEDX could double from here in my opinion.

    Biotech is the place to be.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ACOR: I like the science, the results shown, and most of all, the potential patients/markets it could serve in this indication. It went Mt St Helens on results previously and with an approval (was it two years back-time flies-LOL), I think it could happen again. Maybe a bit more muted move if approved with a partner now, but less risk on the financial side and a good momentum possibility for the fall. Not in yet, but likely will be in the not too distant future!

      VNDA is a simple play to me: They have an approved drug, lots of competitors, big market to try and weasel into to and no sales/marketing-so therefore a marketing partner or a buyout.

      MITI: I like their platform and work to date-not sure this is a ripe bananna yet, but its development has nice potential with some patience. Can't all be about just today-planting seeds here. If I get a surprise-then great.



    • Hey kutz, I also have miti shares and vnda shares and calls. My calls tripled, sold a third, so they are now a free play like hgsi, which is the best way to play this game.

      so, what's compelling with acor?

    • MEDX----No real risk to hang out-I just don't think another offer is coming and considered it time to re-set my bio plays and money. Sold all.

      I added MITI and VNDA to my mix this AM. Both were up decently today. VNDA is a short-term play to me and MITI is mid-term play.

      ACOR jumped today as well-not there yet!


    • On the subject of MEDX: I wouldn't post this on the MEDX board, because it serves MEDX holders' interest if any "2nd bidder" rumors start, but I would not expect one.

      The only time I've seen competing bids is in hostile situations, eg CVTX, and IMCL come to mind.

      With MEDX, one has to assume that since JNJ is the only real likely counter-bidder that they would have been queried for a bid prior to approving the BMY offer. Plus JNJ is practically a stones throw from the MEDX headquarters.

      There's really nothing to lose by holding for a couple of weeks and waiting to see if any rumors materialize.

    • I'm holding a fairly good sized cash hoard myself but I am using it to pick off trades. What's wrong with cash? It served me VERY well over the last 18 months.

      I am still going to be patient...SQNM back near $4...hopefully.

    • bronk: Yea many of my tickers are flying today-LOL. This bio year is swelling my YTD numbers! Much better than last freakin year!

      That SSRX ain't moving much. Maybe the Chinese don't have the AMAG approval news yet-LOL!

      My only mistake currently is I have a very large cash position not in. Could be worse problems-----LOL!


    • Kutz:

      Being lucky sure is fun and profitable.

      I missed one of my favorite orphan companies...CRDC. I got a little greedy, wanted it cheaper and never did buy it. If the market continues through 1000 on S&P, M&A activity should heat up.

    • Congrats on MEDX Bronk: Another couple Biotech hits and it would be a great July in bio history for me!

      Sometimes it just works!


    • I am long. I traded a few times last year, bought back real low earlier this year. It has been steady rise with exception of today's big rise. I am long at least until Ipi trial result early next year.

42.68-0.34(-0.79%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.